ClinicalTrials.gg
CompletedNCT01300260Updated Oct 7, 2014Results posted

Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose

A Phase 1 interventional study of LY2189265 and Placebo in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-07.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
45th of 54
32 · median 159
Started
2011
with 7 others
Phase 1
15 of 54
none open now
Registered
12th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 45th largest by enrollment, is one of 8 that started in 2011, is one of 15 in phase 1, and was the 12th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to measure the effect of LY2189265 to increase insulin levels in response to glucose intake.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Participants

  • Women must be surgically sterile (hysterectomy or bilateral oophorectomy or tubal ligation) or as defined by age >45 years without use of oral agents for greater than 1 year and have either:

    • spontaneous amenorrhea greater than 12 months, or
    • spontaneous amenorrhea 6 to 12 months with documented follicle stimulating hormone (FSH) >25 milli international units/milliliter (mIU/mL) and serum estradiol \<73 picomoles/liter (pmol/L) (20 picograms/milliliter [pg/mL])
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
  • Have given written approved by Lilly and the ethical review board governing the site
  • Have serum creatinine \<150 micromoles/liter (µmol/L) (\<1.3 milligrams/deciliter [mg/dl] in women, \<170 µmol/L [\<1.5 mg/dL] in men)
  • Have normal result, as determined by the investigator

Healthy Participants

  • Overtly healthy men and women as determined by medical history, normal lab results and physical examination.
  • (BMI) between 19 and 25 kilograms/meter squared (kg/m\^2), inclusive.
  • Normal blood pressure and heart rate as determined by the investigator
  • Have a normal response to an oral glucose tolerance test (OGTT) (glucose \<7.8 millimoles/liter [mmol/L] [\<140 mg/dL] at 2 hours after 75 grams (g) oral glucose load)

Participants with type 2 diabetes mellitus (T2DM)

  • Participants will have a BMI between 22.0 and 40.0 kg/m\^2
  • Have T2DM controlled with diet and exercise alone or metformin for at least 4 weeks prior to admission
  • Have a (HbA1c) value at screening (or within 4 weeks prior to screening) of 6.0% to 9.5%
  • Diagnosed with T2DM within the past 10 years
  • Clinical laboratory test results within normal range or deemed clinically insignificant by the Investigator. Abnormalities of serum glucose, serum lipids, urinary glucose, and urinary protein consistent with T2DM are acceptable.
  • Participants who are taking stable-dose prescription medications (for example, antihypertensive agents, aspirin, lipid-lowering agents) for treatment of concurrent medical conditions are permitted to participate providing the medication is not associated with development of torsade de pointes. However, use of beta-blockers and thiazide diuretics are not permitted during this study.

Exclusion criteria

Exclusion Criteria:

All Participants

  • Within 30 days of the initial dose of study drug, have received treatment with a drug that has not received regulatory approval for any indication
  • Known allergies to Glucagon-Like Peptide 1 (GLP-1) related compounds
  • Have previously completed or withdrawn from this study or any other study in the last year investigating glucagon-like peptides or incretin mimetics including exenatide (Byetta®)
  • Regular use of known drugs of abuse and/or positive findings on urinary drug screening, other than findings consistent with medication prescribed by the participant's physician(s)
  • History or presence of cardiovascular, respiratory, renal, endocrine (except T2DM), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs or of constituting a risk when taking the study medication or interfering with the interpretation of data
  • Have a history or presence of gastrointestinal disorder
  • Poorly controlled hypertension (systolic greater than 160 millimeters of mercury [mmHg], diastolic greater than 95 mmHg) and/or evidence of labile blood pressure including symptomatic postural hypotension. Use of beta-blockers or thiazide diuretics is not permitted during the study
  • Have a history of cardiac disease or presence of active cardiac disease within 1 year of the screening period
  • Evidence of and/or positive hepatitis C antibody
  • Evidence of and/or positive hepatitis B surface antigen
  • Evidence of (HIV) and/or positive for HIV antibodies
  • Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females) or are unwilling to follow alcohol restrictions (1 unit = 12 ounces [oz] or 360 milliliters[mL] of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).
  • Smoke more than 10 cigarettes or equivalent in nicotine use or nicotine substitutes per day
  • Regular use of systemic by oral, intravenous, or intramuscular route, or potent, inhaled, or intranasal steroids known to have a high rate of systemic absorption
  • Have a history or presence of significant active neuropsychiatric disease
  • Blood donation of more than 500 mL in the last 3 months or any blood donation within the last month
  • Any other condition, which in the opinion of the investigator would preclude participation in the study
  • An abnormality in the 12-lead (ECG) that in the opinion of the investigator increases the risk of participating in the study.
  • Any clinically significant abnormal hematology, clinical chemistry, or urinary result(s) as determined by the investigator
  • Evidence of significant active uncontrolled endocrine or abnormalities (for example thyroid disease, or pernicious anemia) as judged by the screening physician

Healthy Participants

  • Intended use of over-the-counter or prescription medication 7 and 14 days, respectively, prior to dosing.

Participants with T2DM

  • Clinically significant peripheral vascular occlusive disease (PVOD).
  • Known severe exudative diabetic retinopathy
  • Known significant autonomic neuropathy as evidenced by urinary retention, diabetic diarrhea, or gastroparesis
  • Have experienced a ketoacidotic episode (pH less than 7.3) requiring hospitalization in the last 6 months
  • Outpatient use of insulin for control of diabetes within the past 2 years
  • Use of antidiabetic agents other than metformin in the 4 weeks prior to study entry or use of thiazolidinediones within 12 weeks of study entry
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    LY2189265 then Placebo

    LY2189265 (Dulaglutide) then Placebo: A single 1.5 milligram (mg) subcutaneous (SC) injection of LY2189265 on Day 1 in Period 1, followed by a single SC injection of Placebo on Day 1 in Period 2. On Day 3 of each period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose bolus (0.3 gram/kilogram \[g/kg\] over approximately 2 minutes). Three hours later, participants were administered a second IV dextrose bolus of 25 g of 50% dextrose or a suitably adjusted dose according to glycemic status (20 g of 50% dextrose for participants with 3-hour glucose between 5.2 and 10 millimole/liter \[mmol/L\] or 15 g of 50% dextrose for participants with 3-hour glucose \>10 mmol/L), followed by a 20% dextrose at the set infusion rate of 600 milliliter/hour \[mL/h\] for 35 minutes. Fifteen minutes after the start of the 20% dextrose infusion, an IV 1-mg glucagon bolus was administered. There was a washout period of at least 28 days between Periods 1 and 2.

    Biological: LY2189265 · Drug: Placebo · Drug: Insulin · Drug: Glucose · Drug: Glucagon

  • Experimental
    Placebo then LY2189265

    Placebo then LY2189265 (Dulaglutide): A single subcutaneous injection of Placebo on Day 1 in Period 1, followed by a single 1.5 milligrams (mg) subcutaneous injection of LY2189265 on Day 1 in Period 2. On Day 3 of each period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose bolus (0.3 gram/kilogram \[g/kg\] over approximately 2 minutes). Three hours later, participants were administered a second IV dextrose bolus of 25 g of 50% dextrose or a suitably adjusted dose according to glycemic status (20 g of 50% dextrose for participants with 3-hour glucose between 5.2 and 10 millimole/liter \[mmol/L\] or 15 g of 50% dextrose for participants with 3-hour glucose \>10 mmol/L), followed by a 20% dextrose at the set infusion rate of 600 milliliter/hour \[mL/h\] for 35 minutes. Fifteen minutes after the start of the 20% dextrose infusion, an IV 1-mg glucagon bolus was administered. There was a washout period of at least 28 days between Periods 1 and 2.

    Biological: LY2189265 · Drug: Placebo · Drug: Insulin · Drug: Glucose · Drug: Glucagon

Interventions

  • BiologicalLY2189265

    Administered subcutaneously

    Also known as: Dulaglutide

  • DrugPlacebo

    Administered subcutaneously

  • Administered intravenously

    Also known as: Lispro

  • Administered intravenously

    Also known as: Dextrose

  • Administered intravenously

    Also known as: Glucagon hydrochloride

06

What researchers measure

Primary outcomes

  1. Maximum Insulin Concentration (Cmax) - First Phase Response

    On Day 1 of each treatment period, all participants (healthy or with type 2 diabetes mellitus \[T2DM\]) received a single subcutaneous dose of either LY2189265 or placebo. On Day 3 of each treatment period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose 50% bolus to stimulate insulin secretion. Three hours later, participants were administered a second dextrose bolus, followed by an infusion of 20% dextrose and, 15 minutes after the start of the 20% dextrose infusion, a 1-mg glucagon bolus was administered. Maximum plasma insulin concentration from 0 to 10 minutes (INSCmax\[0-10\]) following the first dextrose bolus (the first phase response) was corrected for baseline, where baseline was the mean of the insulin concentrations obtained between -30 and 0 minutes relative to the first dextrose bolus.

    Time frame: 0-10 minutes after dextrose bolus on Day 3 postdose

  2. Area Under the Insulin Concentration-time Curve (AUC) - First Phase Response

    On Day 1 of each treatment period, all participants (healthy or with type 2 diabetes mellitus \[T2DM\]) received a single subcutaneous dose of either LY2189265 or placebo. On Day 3 of each treatment period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose 50% bolus to stimulate insulin secretion. Three hours later, participants were administered a second dextrose bolus, followed by an infusion of 20% dextrose and, 15 minutes after the start of the 20% dextrose infusion, a 1-mg glucagon bolus was administered. Area under the plasma insulin concentration time curve from 0 to 10 minutes (INSAUC\[0-10\]) following the first dextrose bolus (the first phase response) was corrected for baseline, where baseline was the mean of the insulin concentrations obtained between -30 and 0 minutes relative to the first dextrose bolus.

    Time frame: 0-10 minutes after dextrose bolus on Day 3 postdose

  3. Maximum Insulin Concentration (Cmax) - Second Phase Response

    On Day 1 of each treatment period, all participants (healthy or with type 2 diabetes mellitus \[T2DM\]) received a single subcutaneous dose of either LY2189265 or placebo. On Day 3 of each treatment period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose 50% bolus to stimulate insulin secretion. Three hours later, participants were administered a second dextrose bolus, followed by an infusion of 20% dextrose and, 15 minutes after the start of the 20% dextrose infusion, a 1-mg glucagon bolus was administered. Maximum plasma insulin concentration from 10 to 180 minutes (INSCmax\[10-180\]) following the first dextrose bolus (the second phase response) was corrected for baseline, where baseline was the mean of the insulin concentrations obtained between -30 and 0 minutes relative to the first dextrose bolus.

    Time frame: 10-180 minutes after dextrose bolus on Day 3 postdose

  4. Insulin Area Under the Curve (AUC) - Second Phase Response

    On Day 1 of each treatment period, all participants (healthy or with type 2 diabetes mellitus \[T2DM\]) received a single subcutaneous dose of either LY2189265 or placebo. On Day 3 of each treatment period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose 50% bolus to stimulate insulin secretion. Three hours later, participants were administered a second dextrose bolus, followed by an infusion of 20% dextrose and, 15 minutes after the start of the 20% dextrose infusion, a 1-mg glucagon bolus was administered. Area under the plasma insulin concentration time curve from 10 to 180 minutes (INSAUC\[10-180\]) following the first dextrose bolus (the second phase response) was corrected for baseline, where baseline was the mean of the insulin concentrations obtained between -30 and 0 minutes relative to the first dextrose bolus.

    Time frame: 10-180 minutes after dextrose bolus on Day 3 post dose

Secondary outcomes

  1. Insulin Maximum Concentration (Cmax)

    On Day 1 of each treatment period, all participants (healthy or with type 2 diabetes mellitus \[T2DM\]) received a single subcutaneous dose of either LY2189265 or placebo. Maximum plasma insulin concentration from -2 to 20 minutes following the glucagon bolus (INSCmaxG) is presented.

    Time frame: After glucagon bolus on Day 3 postdose

Other outcomes

  1. Area Under the Insulin Concentration-time Curve (AUC)

    On Day 1 of each treatment period, all participants (healthy or with type 2 diabetes mellitus \[T2DM\]) received a single subcutaneous dose of either LY2189265 or placebo. Area under the plasma insulin concentration-time curve from -2 to 20 minutes following the glucagon bolus (INSAUCG) is presented.

    Time frame: After glucagon bolus on Day 3 postdose

07

Results

Posted Oct 7, 2014

Participant flow

Period 1 of Study: First Intervention
Participant flow — Period 1 of Study: First Intervention
MilestoneLY2189265 First, Then PlaceboPlacebo First, Then LY2189265
Started1517
Received at least 1 dose of study drug1517
Completed1416
Not completed11
Withdrew: Adverse event01
Withdrew: Withdrawal by subject10
Washout Period of at Least 28 Days
Participant flow — Washout Period of at Least 28 Days
MilestoneLY2189265 First, Then PlaceboPlacebo First, Then LY2189265
Started1416
Completed1416
Not completed00
Period 2 of Study: Second Intervention
Participant flow — Period 2 of Study: Second Intervention
MilestoneLY2189265 First, Then PlaceboPlacebo First, Then LY2189265
Started1416
Completed1415
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryMaximum Insulin Concentration (Cmax) - First Phase Response

On Day 1 of each treatment period, all participants (healthy or with type 2 diabetes mellitus \[T2DM\]) received a single subcutaneous dose of either LY2189265 or placebo. On Day 3 of each treatment period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose 50% bolus to stimulate insulin secretion. Three hours later, participants were administered a second dextrose bolus, followed by an infusion of 20% dextrose and, 15 minutes after the start of the 20% dextrose infusion, a 1-mg glucagon bolus was administered. Maximum plasma insulin concentration from 0 to 10 minutes (INSCmax\[0-10\]) following the first dextrose bolus (the first phase response) was corrected for baseline, where baseline was the mean of the insulin concentrations obtained between -30 and 0 minutes relative to the first dextrose bolus.

Time frame:
0-10 minutes after dextrose bolus on Day 3 postdose
Reported as:
Geometric mean · picomole per liter (pmol/L)
Maximum Insulin Concentration (Cmax) - First Phase Response
picomole per liter (pmol/L)Healthy Participants: PlaceboHealthy Participants: LY2189265Participants With Type 2 Diabetes Mellitus (T2DM): PlaceboParticipants With Type 2 Diabetes Mellitus (T2DM): LY2189265
Maximum Insulin Concentration (Cmax) - First Phase Response233 (154 to 352)689 (455 to 1041)74.3 (46.8 to 118)401 (252 to 637)
Statistical analysis
  • Healthy Participants: Placebo vs Healthy Participants: LY2189265 · Mixed Models Analysis · p = <0.001 (P-value is two-sided.) · Geometric least squares (ls) mean ratio: 2.96 · 95% CI 2.41 to 3.64The mixed model analysis included treatment, period, and sequence as fixed effects and participant nested in sequence as a random effect.
  • Participants With Type 2 Diabetes Mellitus (T2DM): Placebo vs Participants With Type 2 Diabetes Mellitus (T2DM): LY2189265 · Mixed Models Analysis · p = <0.001 (P-value is two-sided.) · Geometric least squares (ls) means ratio: 5.40 · 95% CI 4.09 to 7.13The mixed model analysis included treatment, period, and sequence as fixed effects and participant nested in sequence as a random effect.
PrimaryArea Under the Insulin Concentration-time Curve (AUC) - First Phase Response

On Day 1 of each treatment period, all participants (healthy or with type 2 diabetes mellitus \[T2DM\]) received a single subcutaneous dose of either LY2189265 or placebo. On Day 3 of each treatment period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose 50% bolus to stimulate insulin secretion. Three hours later, participants were administered a second dextrose bolus, followed by an infusion of 20% dextrose and, 15 minutes after the start of the 20% dextrose infusion, a 1-mg glucagon bolus was administered. Area under the plasma insulin concentration time curve from 0 to 10 minutes (INSAUC\[0-10\]) following the first dextrose bolus (the first phase response) was corrected for baseline, where baseline was the mean of the insulin concentrations obtained between -30 and 0 minutes relative to the first dextrose bolus.

Time frame:
0-10 minutes after dextrose bolus on Day 3 postdose
Reported as:
Geometric mean · picomole times hour per liter (pmol*h/L)
Area Under the Insulin Concentration-time Curve (AUC) - First Phase Response
picomole times hour per liter (pmol*h/L)Healthy Participants: PlaceboHealthy Participants: LY2189265Participants With Type 2 Diabetes Mellitus (T2DM): PlaceboParticipants With Type 2 Diabetes Mellitus (T2DM): LY2189265
Area Under the Insulin Concentration-time Curve (AUC) - First Phase Response22.9 (15.0 to 34.9)70.7 (46.3 to 108)5.06 (2.90 to 8.83)40.1 (22.8 to 70.3)
Statistical analysis
  • Healthy Participants: Placebo vs Healthy Participants: LY2189265 · Mixed Models Analysis · p = <0.001 (P-value is two-sided.) · Geometric least squares (ls) mean ratio: 3.09 · 95% CI 2.66 to 3.59The mixed model analysis included treatment, period, and sequence as fixed effects and participant nested in sequence as a random effect.
  • Participants With Type 2 Diabetes Mellitus (T2DM): Placebo vs Participants With Type 2 Diabetes Mellitus (T2DM): LY2189265 · Mixed Models Analysis · p = <0.001 (P-value is two-sided.) · Geometric least squares (ls) mean ratio: 7.92 · 95% CI 4.82 to 13.0The mixed model analysis included treatment, period, and sequence as fixed effects and participant nested in sequence as a random effect.
PrimaryMaximum Insulin Concentration (Cmax) - Second Phase Response

On Day 1 of each treatment period, all participants (healthy or with type 2 diabetes mellitus \[T2DM\]) received a single subcutaneous dose of either LY2189265 or placebo. On Day 3 of each treatment period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose 50% bolus to stimulate insulin secretion. Three hours later, participants were administered a second dextrose bolus, followed by an infusion of 20% dextrose and, 15 minutes after the start of the 20% dextrose infusion, a 1-mg glucagon bolus was administered. Maximum plasma insulin concentration from 10 to 180 minutes (INSCmax\[10-180\]) following the first dextrose bolus (the second phase response) was corrected for baseline, where baseline was the mean of the insulin concentrations obtained between -30 and 0 minutes relative to the first dextrose bolus.

Time frame:
10-180 minutes after dextrose bolus on Day 3 postdose
Reported as:
Geometric mean · picomole per liter (pmol/L)]
Maximum Insulin Concentration (Cmax) - Second Phase Response
picomole per liter (pmol/L)]Healthy Participants: PlaceboHealthy Participants: LY2189265Participants With Type 2 Diabetes Mellitus (T2DM): PlaceboParticipants With Type 2 Diabetes Mellitus (T2DM): LY2189265
Maximum Insulin Concentration (Cmax) - Second Phase Response89.2 (64.7 to 123)370 (269 to 511)95.9 (66.3 to 139)363 (250 to 526)
Statistical analysis
  • Healthy Participants: Placebo vs Healthy Participants: LY2189265 · Mixed Models Analysis · p = <0.001 (P-value is two-sided.) · Geometric least squares (ls) mean ratio: 4.15 · 95% CI 3.45 to 5.00The mixed model analysis included treatment, period, and sequence as fixed effects and participant nested in sequence as a random effect.
  • Participants With Type 2 Diabetes Mellitus (T2DM): Placebo vs Participants With Type 2 Diabetes Mellitus (T2DM): LY2189265 · Mixed Models Analysis · p = <0.001 (P-value is two-sided.) · Geometric least squares (ls) mean ratio: 3.78 · 95% CI 2.99 to 4.78The mixed model analysis included treatment, period, and sequence as fixed effects and participant nested in sequence as a random effect.
PrimaryInsulin Area Under the Curve (AUC) - Second Phase Response

On Day 1 of each treatment period, all participants (healthy or with type 2 diabetes mellitus \[T2DM\]) received a single subcutaneous dose of either LY2189265 or placebo. On Day 3 of each treatment period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose 50% bolus to stimulate insulin secretion. Three hours later, participants were administered a second dextrose bolus, followed by an infusion of 20% dextrose and, 15 minutes after the start of the 20% dextrose infusion, a 1-mg glucagon bolus was administered. Area under the plasma insulin concentration time curve from 10 to 180 minutes (INSAUC\[10-180\]) following the first dextrose bolus (the second phase response) was corrected for baseline, where baseline was the mean of the insulin concentrations obtained between -30 and 0 minutes relative to the first dextrose bolus.

Time frame:
10-180 minutes after dextrose bolus on Day 3 post dose
Reported as:
Geometric mean · picomole times hour per liter (pmol*h/L)
Insulin Area Under the Curve (AUC) - Second Phase Response
picomole times hour per liter (pmol*h/L)Healthy Participants: PlaceboHealthy Participants: LY2189265Participants With Type 2 Diabetes Mellitus (T2DM): PlaceboParticipants With Type 2 Diabetes Mellitus (T2DM): LY2189265
Insulin Area Under the Curve (AUC) - Second Phase Response68.8 (41.7 to 114)141 (85.3 to 232)147 (103 to 209)357 (250 to 511)
Statistical analysis
  • Healthy Participants: Placebo vs Healthy Participants: LY2189265 · Mixed Models Analysis · p = 0.011 (P-value is two-sided.) · Geometric least squares (ls) mean ratio: 2.04 · 95% CI 1.26 to 3.31The mixed model analysis included treatment, period, and sequence as fixed effects and participant nested in sequence as a random effect.
  • Participants With Type 2 Diabetes Mellitus (T2DM): Placebo vs Participants With Type 2 Diabetes Mellitus (T2DM): LY2189265 · Mixed Models Analysis · p = <0.001 (P-value is two-sided.) · Geometric least squares (ls) mean ratio: 2.44 · 95% CI 1.71 to 3.47The mixed model analysis included treatment, period, and sequence as fixed effects and participant nested in sequence as a random effect.
SecondaryInsulin Maximum Concentration (Cmax)

On Day 1 of each treatment period, all participants (healthy or with type 2 diabetes mellitus \[T2DM\]) received a single subcutaneous dose of either LY2189265 or placebo. Maximum plasma insulin concentration from -2 to 20 minutes following the glucagon bolus (INSCmaxG) is presented.

Time frame:
After glucagon bolus on Day 3 postdose
Reported as:
Geometric mean · picomole per liter (pmol/L)
Insulin Maximum Concentration (Cmax)
picomole per liter (pmol/L)Healthy Participants: PlaceboHealthy Participants: LY2189265Participants With Type 2 Diabetes Mellitus (T2DM): PlaceboParticipants With Type 2 Diabetes Mellitus (T2DM): LY2189265
Insulin Maximum Concentration (Cmax)996 (716 to 1386)1215 (874 to 1690)1088 (827 to 1431)1514 (1151 to 1991)
Statistical analysis
  • Healthy Participants: Placebo vs Healthy Participants: LY2189265 · Mixed Models Analysis · p = 0.021 (P-value is two-sided.) · Geometric least squares (ls) mean ratio: 1.22 · 95% CI 1.04 to 1.43The mixed model analysis included treatment, period, and sequence as fixed effects and participant nested in sequence as a random effect.
  • Participants With Type 2 Diabetes Mellitus (T2DM): Placebo vs Participants With Type 2 Diabetes Mellitus (T2DM): LY2189265 · Mixed Models Analysis · p = <0.001 (P-value is two-sided.) · Geometric least squares (ls) mean ratio: 1.39 · 95% CI 1.27 to 1.53The mixed model analysis included treatment, period, and sequence as fixed effects and participant nested in sequence as a random effect.
Other pre-specifiedArea Under the Insulin Concentration-time Curve (AUC)

On Day 1 of each treatment period, all participants (healthy or with type 2 diabetes mellitus \[T2DM\]) received a single subcutaneous dose of either LY2189265 or placebo. Area under the plasma insulin concentration-time curve from -2 to 20 minutes following the glucagon bolus (INSAUCG) is presented.

Time frame:
After glucagon bolus on Day 3 postdose
Reported as:
Geometric mean · picomole times hour per liter (pmol*h/L)
Area Under the Insulin Concentration-time Curve (AUC)
picomole times hour per liter (pmol*h/L)Healthy Participants: PlaceboHealthy Participants: LY2189265Participants With Type 2 Diabetes Mellitus (T2DM): PlaceboParticipants With Type 2 Diabetes Mellitus (T2DM): LY2189265
Area Under the Insulin Concentration-time Curve (AUC)239 (167 to 340)341 (239 to 486)236 (177 to 316)414 (310 to 554)
Statistical analysis
  • Healthy Participants: Placebo vs Healthy Participants: LY2189265 · Mixed Models Analysis · p = 0.009 (P-value is two-sided.) · Geometric least squares (ls) mean ratio: 1.43 · 95% CI 1.14 to 1.80The mixed model analysis included treatment, period, and sequence as fixed effects and participant nested in sequence as a random effect.
  • Participants With Type 2 Diabetes Mellitus (T2DM): Placebo vs Participants With Type 2 Diabetes Mellitus (T2DM): LY2189265 · Mixed Models Analysis · p = <0.001 (P-value is 2-sided.) · Geometric least squares (ls) mean ratio: 1.75 · 95% CI 1.59 to 1.94The mixed model analysis included treatment, period, and sequence as fixed effects and participant nested in sequence as a random effect.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healthy Participants: Placebo—0/10 (0%)2/10 (20%)
Healthy Participants: LY2189265—0/10 (0%)6/10 (60%)
Participants With Type 2 Diabetes Mellitus (T2DM): Placebo—0/21 (0%)9/21 (42.9%)
Participants With Type 2 Diabetes Mellitus (T2DM): LY2189265—0/21 (0%)11/21 (52.4%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventHealthy Participants: PlaceboHealthy Participants: LY2189265Participants With Type 2 Diabetes Mellitus (T2DM): PlaceboParticipants With Type 2 Diabetes Mellitus (T2DM): LY2189265
HypoglycaemiaMetabolism and nutrition disorders0/104/100/210/21
VomitingGastrointestinal disorders1/101/100/214/21
HeadacheNervous system disorders0/100/103/212/21
Abdominal distensionGastrointestinal disorders0/101/101/210/21
DyspepsiaGastrointestinal disorders0/101/100/210/21
NauseaGastrointestinal disorders1/100/101/212/21
Infusion site phlebitisGeneral disorders1/100/100/210/21
Injection site oedemaGeneral disorders0/101/101/210/21
Injection site phlebitisGeneral disorders1/100/102/211/21
Injection site thrombosisGeneral disorders0/101/101/210/21

Baseline characteristics

Healthy participants or participants with type 2 diabetes mellitus (T2DM) who received at least one dose of study drug (LY2189265 or Placebo).

Age, Continuous
Age, Continuous(years)Healthy ParticipantsParticipants With Type 2 Diabetes Mellitus (T2DM)Total
Mean51.9 ± 5.056.3 ± 6.154.9 ± 6.1
Sex: Female, Male
Sex: Female, Male(Participants)Healthy ParticipantsParticipants With Type 2 Diabetes Mellitus (T2DM)Total
Female3710
Male71522
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Healthy ParticipantsParticipants With Type 2 Diabetes Mellitus (T2DM)Total
Hispanic or Latino000
Not Hispanic or Latino102232
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Healthy ParticipantsParticipants With Type 2 Diabetes Mellitus (T2DM)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White102232
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Healthy ParticipantsParticipants With Type 2 Diabetes Mellitus (T2DM)Total
Germany102232
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Neuss, D-41460, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2011
First posted
Feb 21, 2011
Start
Feb 2011
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Oct 7, 2014
Last update
Oct 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01300260
Responsible party
Sponsor
First posted
Feb 21, 2011
Start date
Feb 2011
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Oct 7, 2014
Last update
Oct 7, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion